Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
05 mai 2022 11h55 HE
|
Zai Lab Limited
- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types...
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
28 avr. 2022 07h30 HE
|
Zai Lab Limited
91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the...
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
21 avr. 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022
20 avr. 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Plants a Tree for Every Employee on Earth Day 2022
19 avr. 2022 08h00 HE
|
Zai Lab Limited
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
06 avr. 2022 08h01 HE
|
Zai Lab Limited
- First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation - Poster presentations will feature three additional candidates of Zai Lab’s internal...
Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022
23 mars 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, and CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
20 mars 2022 20h00 HE
|
Zai Lab Limited
PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study population regardless of...
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
15 mars 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
01 mars 2022 16h05 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...